ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $16.56M, compared with -$24.43M a year earlier. Trailing-twelve-month net change in cash was $12.24M.
Context
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $16.56M or moves back toward the trailing-twelve-month quarterly average of $3.06M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (28.75M) USD
- Year-over-year change
- +62.2%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.75M) | +62.2% |
| FY2024 | 2024-12-31 | (76.1M) | -486.1% |
| FY2023 | 2023-12-31 | (12.98M) | -110.3% |
| FY2022 | 2022-12-31 | 126.09M | +238.2% |
| FY2021 | 2021-12-31 | 37.28M | — |
Net Change in Cash vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 net change in cash of $12.24M is the 10th largest of the 11 companies compared; the peer median is $4.35M.
- Its year-over-year change of +104.6% is the 4th highest of 11, against a peer median of -25.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $203.95M | -736.8% | +8.7% | 33.9% | |
| LTM Jun 2026 | $124.74M | -222.0% | +73.0% | 27.7% | |
| LTM Jul 2026 | $117.02M | +443.9% | — | 4.8% | |
| LTM Mar 2026 | $68.35M | -193.6% | -21.2% | — | |
| LTM Sep 2026 | $48.73M | +3523.0% | — | — | |
| LTM Jun 2026 | $48.53M | -77.3% | — | 28.6% | |
| LTM Mar 2026 | $27.53M | +26.9% | — | 12.2% | |
| LTM Mar 2026 | $26.84M | +95.6% | — | 11.8% | |
| LTM Mar 2026 | $15.77M | -89.7% | -34.1% | — | |
| LTM Mar 2026 | $12.24M | +104.6% | — | — | |
| LTM Mar 2026 | $7.06M | +200.5% | -55.8% | — | |
| Peer median (excluding AVBP) | $4.35M | -25.2% | -21.2% | 20.0% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.